Regulatory filing 📈 Stocks 🌍 United States

Shuttle Pharmaceuticals Issues 6.69 Million Pre-Funded Warrants

Shuttle Pharmaceuticals issued 6,693,740 pre-funded warrants at $0.001 per share after meeting milestone conditions, with mandatory resale registration deadlines set between January 2027 and May 2027.

🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 1 Bearish, 0 Neutral. Strongest signal: SHPH ↓ 7/10 (75% confidence).

📊 Affected Assets (1)

SHPH
Bearish 🤖 75%
📅 Short-term 🌍 US · Explicit

On November 13, 2026, the company determined the Milestone Events were satisfied and issued pre-funded warrants exercisable immediately for up to 6,693,740 common shares at $0.001 per share with no cash consideration received, a large potential share count increase for a small Nasdaq company. The SPA Amendment also locks in mandatory registration statements (by January 31 to May 1, 2027) that will make these resale shares freely tradable, adding overhang. Dilution of this size typically pressures a micro-cap price.

Catalysts
  • ▼ Issuance of pre-funded warrants for 6,693,740 shares at $0.001 exercise price on November 13, 2026 with no cash consideration
  • ▼ Mandatory resale registration statements due January 31, 2027 through May 1, 2027 for Conversion, Warrant and Milestone Shares
Risk Factors
  • ▲ Potential dilution only materializes when warrants are exercised and resale registrations become effective
  • ▲ Registration statements could be delayed up to 90 days if the SEC reviews them

🎯 Key Takeaways

  • Shuttle Pharmaceuticals issued 6,693,740 pre-funded warrants on November 13, 2026, with an exercise price of $0.001 per share.
  • The company received no additional cash consideration for the issuance of these warrants.
  • Registration statements for the resale of these shares must be filed in stages between January 31, 2027, and May 1, 2027.
  • Milestone Event conditions were amended to reduce the required Mining Rigs threshold from 2,000 to 500.

📝 Executive Summary

Shuttle Pharmaceuticals Holdings, Inc. announced on November 13, 2026, the issuance of pre-funded warrants for 6,693,740 common shares at an exercise price of $0.001 per share. The company received no additional cash for these warrants, which were issued following the satisfaction of specific Milestone Events. The firm also established a mandatory registration schedule for these shares, running from January 31, 2027, through May 1, 2027.

❓ FAQ

What did Shuttle Pharmaceuticals announce in this 8-K?

On November 13, 2026 it amended its April 30, 2026 Securities Purchase Agreement and, having decided the Milestone Events were met, issued pre-funded warrants to buy up to 6,693,740 common shares at $0.001 per share, receiving no additional cash for them.

Why does this matter for the stock price?

Pre-funded warrants exercisable immediately at $0.001 mean shares can be obtained essentially for free, and the company must register them for resale between January 31, 2027 and May 1, 2027, which could significantly increase the number of shares on the market relative to the existing float.